Your browser doesn't support javascript.
loading
Impact of NFIB and CYP1A variants on clozapine serum concentration-A retrospective naturalistic cohort study on 526 patients with known smoking habits.
Lenk, Hasan Çagin; Løvsletten Smith, Robert; O'Connell, Kevin S; Jukic, Marin M; Kringen, Marianne Kristiansen; Andreassen, Ole A; Ingelman-Sundberg, Magnus; Molden, Espen.
Afiliação
  • Lenk HÇ; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
  • Løvsletten Smith R; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway.
  • O'Connell KS; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
  • Jukic MM; Division of Mental Health and Addiction, NORMENT Centre, Oslo University Hospital, Oslo, Norway.
  • Kringen MK; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Andreassen OA; Division of Mental Health and Addiction, NORMENT Centre, Oslo University Hospital, Oslo, Norway.
  • Ingelman-Sundberg M; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Molden E; Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Clin Transl Sci ; 16(1): 62-72, 2023 01.
Article em En | MEDLINE | ID: mdl-36152308
ABSTRACT
Clinical response of clozapine is closely associated with serum concentration. Although tobacco smoking is the key environmental factor underlying interindividual variability in clozapine metabolism, recent genome-wide studies suggest that CYP1A and NFIB genetic variants may also be of significant importance, but their quantitative impact is unclear. We investigated the effects of the rs2472297 C>T (CYP1A) and rs28379954 T>C (NFIB) polymorphisms on serum concentrations in smokers and nonsmokers. The study retrospectively included 526 patients with known smoking habits (63.7% smokers) from a therapeutic drug monitoring service in Norway. Clozapine dose-adjusted concentrations (C/D) and patient proportions with subtherapeutic levels (<1070 nmol/L) were compared between CYP1A/NFIB variant allele carriers and homozygous wild-type carriers (noncarriers), in both smokers and nonsmokers. Clozapine C/D was reduced in patients carrying CYP1A-T and NFIB-C variants versus noncarriers, both among smokers (-48%; p < 0.0001) and nonsmokers (-35%; p = 0.028). Patients who smoke carrying CYP1A-T and NFIB-C variants had a 66% reduction in clozapine C/D versus nonsmoking noncarriers (p < 0.0001). The patient proportion with subtherapeutic levels was 2.9-fold higher in patients who smoke carrying NFIB-C and CYP1A-T variants versus nonsmoking noncarriers (p < 0.0001). In conclusion, CYP1A and NFIB variants have significant and additive impact on clozapine dose requirements for reaching target serum concentrations. Patients who smoke carrying the studied CYP1A and NFIB variants, comprising 2.5% of the study population, may need threefold higher doses to prevent risk of clozapine undertreatment. The results suggest that pre-emptive genotyping of NFIB and CYP1A may be utilized to guide clozapine dosing and improve clinical outcomes in patients with treatment-resistant schizophrenia.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos / Clozapina Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Transl Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Noruega

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos / Clozapina Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Transl Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Noruega